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Synopsis
Wnt proteins are secreted cytokines and several Wnts are expressed in the developing somites and surrounding
tissues. Without proper Wnt stimulation, the organization of the dermomyotome and myotome can become defective.
These Wnt signals received by somitic cells can lead to activation of Pax3/Pax7 and myogenic regulatory factors
(MRFs), especially Myf5 and MyoD. However, it is currently unknown whether Wnts activate Myf5 and MyoD through
direct targeting of their cis-regulatory elements or via indirect pathways. To clarify this issue, in the present study, we
tested the regulation of MyoD cis-regulatory elements by Wnt3a secreted from human embryonic kidney (HEK)-293T
cells. We found that Wnt3a activated the MyoD proximal 6.0k promoter (P6P) only marginally, but highly enhanced
the activity of the composite P6P plus distal enhancer (DE) reporter through canonical and non-canonical pathways.
Further screening of the intervening fragments between the DE and the P6P identified a strong Wnt-response element
(WRE) in the upstream − 8 to − 9k region (L fragment) that acted independently of the DE, but was dependent on
the P6P. Deletion of a Pax3/Pax7-targeted site in the L fragment significantly reduced its response to Wnt3a, implying
that Wnt3a activates the L fragment partially through Pax3/Pax7 action. Binding of β -catenin and Pax7 to their target
sites in the DE and the L fragment respectively was also demonstrated by ChIP. These observations demonstrated
the first time that Wnt3a can directly activate MyoD expression through targeting cis-elements in the DE and the L
fragment.
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INTRODUCTION
Trunk skeletal muscle (SKM) cells in vertebrates are derived from
precursors in the embryonic somites, and a subset of somitic cells
become myogenic stem cells after being specified by local signals
to express Pax3 and Pax7 [1]. They are further confined within
the myogenic lineage by the expression of either MyoD or Myf5
that drives them to become myoblasts. Upon the stimulation of
differentiation signals, myoblasts start expressing myogenin and
Mef2c that co-operatively drive the formation of multinucleated
myotubes, the expression of contractile proteins and cell cycle
exit. Myogenic stem cells are gradually confined to the periphery
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of mature myotubes during late embryogenesis to become satel-
lite cells that are responsible for postnatal muscle growth and
repair [2].
In mice, the expression of Myf5 and MyoD initiates at 8.5
and 10.5 days postcoitum (dpc) respectively, whereas the order
of their expression is reversed in chicken [3–5]. Mice carrying
a Myf5 homozygous mutation die at birth due to the absence
of the distal parts of the ribs, which results in the inability to
breathe [6]; however, the expression levels of other myogenic
regulatory factors (MRFs) in Myf5-null mice appear to be nor-
mal. Surprisingly, MyoD-null mice are fully viable and show
no obvious muscle abnormalities [7]. Since mice carrying null
mutations in either the Myf5 or the MyoD gene have apparently
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normal SKM, it raises the possibility that these two myogenic
factors are functionally redundant in myogenesis. This specula-
tion was confirmed when mice carrying null mutations in both
Myf5 and MyoD loci were found to have a complete absence of
SKM and desmin-expressing myoblast-like cells [8]. These ob-
servations suggest that either Myf5 or MyoD is required for the
determination of skeletal myoblasts or their propagation, or both,
during embryonic myogenesis.
It was surprising to find that MyoD-null mice shown severe
deficiency in regenerative capacity after injury, suggesting that
MyoD plays critical roles in regulating the postnatal myogenic
program of satellite cells [9]. Quiescent satellite cells express
low or undetectable levels of MyoD, but increase their MyoD
expression upon receiving activation signals for proliferation.
High MyoD levels repress satellite cell self-renewal and drive
their myogenic differentiation or apoptosis [10]; therefore the
level of MyoD plays critical roles in the regulation of satellite
pool replenishment and the ability to regenerate damaged tissue.
The expression pattern of human MyoD during embryogenesis
can be recapitulated by the upstream 24 kb flanking sequence, and
several major cis-elements within this region regulating MyoD
expression have been identified [11]. A distal enhancer (DE)
centred at − 20 kb, when combined with a − 2.5k proximal pro-
moter, can also recapitulate human MyoD expression in vivo,
demonstrating its critical role in determining the spatiotemporal
expression of human MyoD [12]. A proximal 6 kb promoter
(P6P) sequence of the mouse MyoD gene containing a proximal
regulatory region (PRR) and a distal regulatory region (DRR) are
sufficient to activate muscle-specific expression of MyoD in vitro
and in vivo, but leaky expression in the central nervous system
and delayed expression in limb buds and bronchial arches were
observed [13,14]. Currently, it is unknown whether the combina-
tion of mouse DE and P6P sequences can faithfully drive MyoD
expression in vivo.
The Wnt protein family consists of 19 secreted paracrine gly-
coproteins that act by binding to Frizzled receptors on target cell
plasma membrane [15]. Multiple intracellular signalling path-
ways can be activated by Wnt–receptor interaction, of which
inactivation of glycogen synthase kinase 3β (GSK3β) leading to
the cytoplasmic accumulation and nuclear import of β-catenin is
the best characterized and is known as the canonical Wnt pathway.
Nuclear β-catenin dimerizes with T-cell factor (TCF)/lymphoid
enhancer factor (LEF) on target gene promoters to drive their tran-
scription to mediate cellular responses to Wnt signals. In addition,
Wnt–receptor-activated pathways can also activate cytoplasmic
c-Jun N-terminal kinase (JNK) and nuclear factor of activated
T-cells (NFAT) to allow them to translocate into the nucleus to
activate target genes [16].
Several Wnts are expressed in somites and surrounding tissues
and are implicated in myogenesis. Wnt1, Wnt3a and Wnt4 are ex-
pressed in the dorsal neural tube; Wnt4, Wnt6 and Wnt7a are ex-
pressed in the dorsal ectoderm; Wnt11 is expressed in the epaxial
dermomyotome [15,17]. These Wnt signals received by somitic
cells can lead to activation of Pax3/Pax7 and/or MRFs. Without
proper Wnt stimulation, the organization of the dermomyotome
and myotome can become defective [18]. A combination of
Wnts in the dorsal neural tube co-operates with a low level
of Sonic Hedgehog (Shh) to induce the expression of Myf5 in
epaxial myotome. At the same time, MyoD is induced in the
hypaxial myotome by the ectodermally derived Wnts and the
lateral plate mesoderm-released bone morphogenetic protein 4
(BMP4) and fibroblast growth factor 5 (Fgf5). Neural tubes of
later stages (>10.5 dpc) can also induce MyoD expression in
epaxial myotomes, indicating the transition in either the compet-
ence of the myotomic cells to Wnt induction or in the composition
of neural-tube-derived Wnts [19].
In resting adult muscle, Wnt5a, Wnt5b, Wnt7a and Wnt4 are
expressed, and the expression of the first three Wnts increases in
the early phase of muscle injury. In the later stages, Wnt7b and
Wnt3a become detectable [20]. Application of Wnt3a in the early
phase of muscle regeneration induced premature differentiation
of progenitor cells, thereby leading to depletion of the satellite
cell pool. In aged mice, systemic Wnt signals induce myogenic
stem cells into fibrogenic cells and thus reduce the regenerative
capability of SKM in aged subjects [21]. Therefore the subtle
regulation of satellite cells by Wnt in adult SKM plays critical
roles in SKM regeneration and aging.
The expression of Myf5 and MyoD has been shown to be
activated by Wnts differentially: Wnt1 and Wnt7a preferentially
activate Myf5 and MyoD respectively, whereas Wnt4, Wnt5 and
Wnt6 activate both MRFs at an intermediate level; the expression
of MyoD was also found to be enhanced by Wnt3a during directed
myogenic differentiation of P19 cells [22–24]. However, it is
currently unknown whether Wnts activate MyoD through direct
targeting of their cis-regulatory elements or via indirect pathways.
To clarify this issue, detailed study on the cis-elements of MyoD
gene regulatory regions is required.
MATERIALS AND METHODS
Plasmids
The MyoD promoter region − 5870 to + 95 was PCR-
amplified using primers (NCUTC021003/NCUTC021004) from
MD6.8-lacZ (a gift from Dr Atsushi Asakura) and inserted
into the KpnI/NheI sites of pStable-luc vector [25] to gen-
erate pStable-MyoD 6.0-luc reporter. A linker sequence (5′-
GTACGAATTCACGCGTGTAC-3′) containing the EcoRI/MluI
sites was inserted into the KpnI site of the above plasmid to gen-
erate pStable-MyoD 6.0-adaptor-luc reporter, which was further
modified to become pStable-MyoD 6.0-enhance-luc (PE) by in-
serting the distal enhancer ( − 25277 to − 20781) amplified from
mouse genomic bacterial artificial chromosome (BAC) clone
(RP23-284P22) into the EcoRI site. Genomic fragments between
the promoter and the core enhancer were PCR-amplified from
the above BAC clone using the primers listed in Supplementary
Table S1 and inserted into the PE reporter for screening their
involvement in Wnt3a response. Wnt3a coding sequence was re-
leased from PGK-puro-Wnt3a (a gift from Dr Ilona Skerjanc)
by BamHI/XhoI and inserted into XhoI (blunted) site of the
pPyCAG-IP vector for creating pPyCAG-IP-Wnt3a expression
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vector. The coding sequences of β-Catenin 90 and 151 were
PCR-amplified and inserted into pCMV-Flag vector to create C-
terminally FLAG-tagged proteins. Then, both coding sequences
were released and inserted into the EcoRI site of pCDNA3.1 and
the XhoI site of pPyCAG-IP vectors to create mammalian expres-
sion vectors that can be stably integrated into chromosomes. The
expression vectors of both dominant-negative NFAT and JNK1
were gifts from Dr Roger Davis [26].
Stable cloning of reporters and promoter assay
Proliferating C2C12 cells were kept at low confluence in Dul-
becco’s modified Eagle’s medium (DMEM) supplemented with
20 % (v/v) FBS. For inducing myotube formation, confluent my-
oblasts were kept in differentiation medium (DMEM supplemen-
ted with 25 nM insulin and 5 mM LiCl) for 4–6 days, before being
harvested for staining and photographing. The stable cloning of
pStable-luc based reporter into C2C12 was as described previ-
ously [27]. Briefly, aliquots (approximately 5 μg) of pStable-
MyoD 6.0-luc (or other derived reporters) DNA were mixed
1:5 with LipofectamineTM (Invitrogen) in Hepes buffer (20 mM
Hepes, pH 7.0, 187 mM NaCl, 5 mM KCl, 0.7 mM Na2HPO4 and
5.5 mM dextrose) in 1.5 ml tubes and incubated at room temper-
ature for 10–15 min to allow DNA and liposome complexes to
form. Then, the mixture was transferred to cells grown in 6-mm-
diameter Petri dishes and the transfection was allowed to proceed
overnight before the medium was replaced by fresh medium.
G418 (800 μg/ml) was added to the medium 48 h after transfec-
tion and the selection was allowed to proceed for 2–3 weeks until
monoclonal colonies appeared. Colonies were pooled together
to form polyclonal population and used for promoter assay. The
stable clones of cells carrying other MyoD cis-element-driven
reporters were similarly generated. Human embryonic kidney
(HEK)-293T cells were kept in DMEM supplemented with 10 %
(v/v) FBS. For establishing stable clones of HEK-293T-Wnt3a
cells, pPyCAG-IP-Wnt3a was transfected into HEK-293 cells
and selected with puromycin (3 μg/ml) as above.
For transient transfection assay, C2C12 cells were split into
12-well plates and allowed to grow to 70–80 % confluence.
Then, cells were co-transfected with promoter-driven reporters
(0.67 μg/well) and expression vectors (0.17 μg/well) for 16 h as
described above for stable cloning of reporters, and then treated
with pathway inhibitors or other compounds for 24 h before be-
ing harvested for determining their luciferase activity using the
Bio-Tek Clarity 2 luminometer. All reactions were carried out in
triplicate and repeated at least three times.
Somite explant culture
Embryos of 10.5 dpc were dissected out from the uterus and
washed extensively with PBS. Then, visceral mass, head, tail
and limbs were carefully removed under a dissection micro-
scope. Somites were cultured in control (pPyCAG-IP) or Wnt3a-
containing medium for 48 h before being harvested for isolating
total RNA. The animal experiments had been approved by the In-
stitutional Animal Care and Use Committee (IACUC) of National
Central University.
Western blot and quantitative reverse
transcription–PCR (qRT-PCR)
The RNA extraction and qRT-PCR procedures have been de-
scribed in our previous papers [25,27]. Briefly, total RNA was
extracted from the C2C12 cells using TRIzol® (Life Techno-
logies) according to the supplier’s instructions. Then, the first
strand of cDNA was synthesized using the Superscript III kit
(Life Technologies). qRT-PCR was performed in 25 μl reac-
tion volumes containing 5 μM forward/reverse primers, SYBR
Green reaction mixture (Applied Biosystems) in an ABI 7300
sequence detection system. Glyceraldehyde-3-phosphate dehyd-
rogenase (Gapdh) was used as an internal control and amplified in
the same PCR assay. All PCR amplicons cover at least one intron
to avoid amplification of genomic DNA in the PCR and primer
sets used for each gene are listed in Supplementary Table S2.
The protocol for Western blotting has been described previ-
ously [25]. Briefly, aliquots of total lysate (50 μg) in RIPA buffer
supplemented with protease inhibitors and phosphatase inhibitors
were separated by SDS/PAGE (10 % gels) before being blotted
on to a PVDF membrane (Pall FluoroTrans W membrane). The
PVDF membranes were washed extensively with PBS contain-
ing 0.5 % Tween 20 (PBST) and blocked with 5 % (w/v) dried
skimmed milk powder in PBST. Primary antibody was diluted
1:1000 in blocking solution and incubated with the blot at 4 ◦C for
overnight. After several washes with PBST, horseradish perox-
idase (HRP)-conjugated secondary antibody (1:10000 dilution)
was added and incubated at room temperature for 1 h. After ex-
tensive washing, the HRP signal was detected by a chemilumin-
escence kit (GE Healthcare). The antibodies against Wnt3a and
Pax7 were purchased from Cell Signaling Technology (#C64F2)
and Neuromics (#MO15020) respectively.
ChIP assay
The detailed procedure of the ChIP assay has been described
in our previous papers [25,28,29]. Briefly, C2C12 cells were
washed, fixed in formaldehyde (1 %, w/v), and sonicated to shear
chromatin. Specific antibody was added to the cleared lysate
and the binding was allowed to proceed at 4 ◦C overnight before
Staphylococcus aureus Protein A (Sigma, #P7155) was added
to capture the immune complex and then washed extensively.
Then, the immune complex was eluted and the released DNA
was extracted with phenol/chloroform twice and further purified
using a PCR purification Kit (Geneaid). The primer sets used in
the ChIP assay are listed in Supplementary Table S3.
RESULTS
Wnt3a activate MyoD expression in myoblasts and
somite explants
Wnt3a is post-translationally modified and these modifications
are critical to its function; therefore recombinant proteins ex-
pressed in bacteria might not be an effective source for treat-
ing mammalian cells. To ensure proper post-translational modi-
fications, the coding sequence of Wnt3a was overexpressed in
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HEK-293T cells by super-transfection, in which the vector
pPyCAG-IP (Py hereinafter) carrying the Wnt3a coding sequence
could replicate extensively in HEK-293T cells to express high
levels of Wnt3a [30]. The expression of Wnt3a in HEK-293-
Wnt3a cell lysates and various culture media was determined
by Western blotting, and we found that serum was critical for
its accumulation in the medium (Figure 1A). Wnt3a protein in
the medium reached its highest level 2 days after cells became
confluent (Figure 1B). Medium harvested at this time point was
routinely collected as the source of Wnt3a (denoted as Wnt3a me-
dium) and it could strongly activate the Wnt signalling pathway
reporter TOPflash (Figure 1C), indicating that Wnt3a secreted
from HEK-293T-Wnt3a cells is functional.
To examine the effect of Wnt3a on MyoD expression, C2C12
myoblasts were kept in control (Py) or Wnt3a-containing me-
dium and their MyoD mRNA level was determined by qRT-PCR.
We found that Wnt3a had no effect on the MyoD mRNA level in
proliferating C2C12 myoblasts, but enhanced its expression sig-
nificantly in confluent myoblasts (Figure 1D), suggesting that the
Wnt3a signalling pathway promotes transcription of the MyoD
gene in a differentiation stage-dependent manner. The same ac-
tivation effect on the MyoD mRNA levels of cultured somite
explants from mouse embryos of 10.5 dpc was also observed
(Figure 1E), demonstrating that the Wnt3a prepared in the present
study can also activate somitic cells to express MyoD.
Cis-elements in distal enhancer mediate Wnt3a
response
It was of interest to decipher how Wnt3a activates MyoD tran-
scription and to clarify whether it targeted the MyoD gene dir-
ectly or through activation of other upstream regulators. To
this end, C2C12 myoblasts stably carrying the P6P ( − 5870 to
+ 95) -driven reporter (MyoD-P6P-luc) or another composite re-
porter, MyoD-PE-luc, containing P6P plus the DE ( − 25277 to
− 20780) (Figure 2A) were treated with Wnt3a medium. We
found that Wnt3a marginally, but significantly, activated MyoD-
P6P-luc activity (Figure 2B); however, Wnt3a strongly activated
MyoD-PE-luc, suggesting that one or multiple Wnt-response ele-
ments (WREs) are located within the DE.
Using a bioinformatics tool (http://www.genomatix.de/
matinspector), we found multiple putative TCF/LEF-binding
sites (T1–T6, matrix similarity >0.9) in the DE. To identify and
confirm that these putative WREs in the DE were responsible
for the Wnt3a response, the DE was first separated into four
fragments of approximately 1.5 kb (Figure 2C, fragments 1–4).
Unfortunately, none of these fragments fully retained Wnt3a-
induced activation (Figure 2D), suggesting that multiple weak
WREs scattered within the DE region are responsible for the
strong Wnt3a activation. Serial deletion mutants of DE region
were generated later to identify the minimal WRE (Figure 2C),
and we found that a region of 3 kb (fragment 10, − 24 to − 21 kb)
in DE was required to retain the full Wnt3a response (Figure 2D).
Deletion of sequence at either the 5′ end (fragment 8) or the 3′ end
(fragment 7) significantly reduced its Wnt3a response, compared
with fragment 10. These results suggest that the outer two flank-
ing TCF/LEF-binding sites (T1 and T6) in DE play an essential
role in its response to Wnt3a.
Multiple pathways are employed to activate distal
enhancer
As the Wnt signal could be transduced by three independent
pathways, it was of interest to know whether Wnt3a was pref-
erentially transduced by any one of them. By co-expressing
dominant-negative end effectors of these pathways, namely β-
catenin, NFAT and JNK, we found that all dominant-negative
effectors partially repressed the Wnt3a response (Figure 3A),
suggesting that all three pathways were employed by Wnt3a
to activate MyoD-PE-luc. The involvement of these pathways
was further tested by applying inhibitors of mitogen-activated
protein kinase (MAPK) pathways and Ca2 + ionophore A23187
to this assay system. The specific inhibitor of the JNK path-
way, SP600125, was the only inhibitor found to partially block
Wnt3a-activated MyoD-PE-luc (Figure 3B), confirming the in-
volvement of the JNK pathway. In contrast, the activation of the
Ca2 + signalling pathway by Ca2 + ionophore A23187 failed to
alter either the basal activity or the Wnt3a response of MyoD-
PE-luc (Figure 3B), suggesting that NFAT, as reported previously
[31], might be indirectly activated by GSK3β instead of the Ca2 +
signalling pathway. The involvement of the canonical pathway
was analysed further and we found that the engrail–β-catenin fu-
sion protein that functions as a dominant-negative homologue of
β-catenin [24], repressed MyoD-PE-luc dose-dependently (Fig-
ure 3C). LiCl, the inhibitor of GSK3 enzymes, also activated
MyoD-PE-luc to a level similar to that triggered by Wnt3a and
in a dose-dependent manner (Figures 3D and 3E), demonstrat-
ing further the involvement of the canonical Wnt pathway in the
activation of MyoD gene by targeting its DE.
Overexpression of constitutively active β-catenin
enhances MyoD expression
To explore further the roles of the canonical Wnt3a pathway in
regulating MyoD expression in vivo, the effect of constitutively
active forms of β-catenin lacking the GSK3β-targeted N-terminal
regions [32] on both MyoD promoter activity and endogen-
ous MyoD expression were examined. We found that β-catenin
151, but not 90, activated MyoD-PE-luc significantly (Fig-
ure 4A), therefore this active mutant was chosen to examine
the regulation of endogenous MyoD by β-catenin. Surprisingly,
overexpression of β-catenin 151–FLAG significantly reduced
the fusion index (nuclei in myotube/total nuclei) of differentiated
myotubes (Figures 4B and 4C). However, the expression levels
of MyoD in β-catenin 151-overexpressed C2C12 cells of con-
fluent myoblast (CMB) and myotube (MT) stages were higher
than that in control cells of the same stages (Figure 4D), demon-
strating the activation effect of the canonical Wnt signal pathway
on endogenous MyoD expression.
As shown in Figure 2(C), the two flanking TCF/LEF
sites, T1 (5′-TCCATTTCAAAGGCCCA-3′) and T6 (5′-
TGCTTCTTTGATGCTTC-3′), seemed to play important roles in
the Wnt3a response, therefore it was of interest to verify whether
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Figure 1 Establishment of Wnt3a-secreting HEK-293T stable clones
(A) The Wnt3a levels (in 20 μl of medium) accumulated in the last 24 h of HEK-293T-Py and -Wnt3a stable clones cultured in
serum-free medium or regular medium (with 10 % FBS) was determined by Western blotting. (B) Growth medium (containing
10 % FBS) from HEK-293T-Wnt3a cells was collected on day 1 and day 2 after cells became confluent. Different volumes
of this medium were then subjected to Western blotting using anti-Wnt3a antibody. Total lysate (50 μg) from cells kept in
medium containing 10 % FBS was used as positive control. (C) Either TOPflash or FOPflash was transiently transfected into
C2C12 myoblasts and then treated with medium from HEK-293T-Py or -Wnt3a cells for 24 h before being harvested for
determination of luciferase activity. The activity in cells treated with Py medium was set as 1-fold activation. **P < 0.01
compared with Py medium. (D and E) Wnt3a activates MyoD expression in C2C12 cells (D) and in somite explants (E). The
expression level of MyoD in proliferating (PMB) and confluent (CMB) C2C12 cells and in cultured somite explants treated
with or without Wnt3a medium was determined by qRT-PCR. The MyoD level in cells or somites treated with Py medium
was set as 1-fold. **P < 0.01 compared with Py medium.
these two sites in the genome were targeted by β-catenin. Using
a ChIP assay, we found that β-catenin 151–FLAG specifically
bound to the T1 and T6 sites in C2C12 cells of the CMB stage
(Figure 4E), confirming their participation in the MyoD gene
response to Wnt3a intracellularly.
A genomic fragment between the DE and the P6P in
the MyoD gene also mediates the Wnt3a response
Previous studies on MyoD gene regulation focused mostly on the
P6P and the DE; the roles of cis-elements in other regions were
seldom investigated. Whether cis-elements outside the P6P and
the DE participate in the Wnt3a response is also an open ques-
tion. The Wnt3a-targeted region in the MyoD gene was dissected
further by inserting individual genomic fragments (approxim-
ately 1–1.5 kb each) located between the DE and the P6P into
the MyoD-PE-luc reporter to mimic their location in vivo (Fig-
ure 5A). Surprisingly, insertion of a non-specific spacer sequence
of comparable size (1 kb) reduced the Wnt3a-induced activation
(Figure 5B, SP), implying that the DE functions in a distance-
sensitive manner. Insertion of most intervening fragments shown
a similar effect, but inclusion of the E, F, K or N fragment
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Figure 2 Wnt3a activates MyoD expression via distal enhancer
(A) Schematic diagrams of the construction of MyoD promoter-driven reporters. The genomic organization of the MyoD
gene is shown on the top. Reporters driven by the proximal 6.0k promoter (P6P) or P6P plus the distal enhancer were
named MyoD-P6P-luc and MyoD-PE-luc respectively. An MluI site between the promoter and enhancer allows insertion
of other genomic fragments. The activation of both reporters by Wnt3a is shown in (B). (C) Diagrams showing various
MyoD-PE-luc-derived reporters in which the DE was replaced by various individual DE fragments. Multiple putative TCF/LEF
target sites (T1–T6, blue boxes) in the DE and the conserved core enhancer (258 bp, orange box) are indicated. The
responses of these reporters to Wnt3a are shown in (D). *P < 0.05 and **P < 0.01 compared with full-length (FL) DE. All
reporters used were stably carried by C2C12 cells.
further reduced Wnt3a-induced activation, suggesting the exist-
ence of putative repressor-binding sites in these fragments. Of
these intervening fragments, fragment L ( − 9489 to − 7890) was
the only one showing a positive effect on Wnt3a-induced MyoD-
PE-luc activation and it invited more effort to decide whether
extra WREs could be found in this fragment.
Wnt3a activates the L fragment via both canonical
and Pax3/Pax7-mediated pathways
The identification of extra WREs in the L fragment revealed
complex transcriptional regulation of MyoD and pointed out the
important involvement of cis-elements located outside the P6P
and the DE regions in MyoD gene transcriptional activation. The
L fragment was tested for its function independently of the DE,
and we found that the L fragment alone could confer a strong
P6P response to Wnt3a, which was significantly higher than that
conferred by the DE (Figure 5C), indicating that the L frag-
ment response to Wnt3a was strongly independent of the DE.
It was of interest to know whether the L fragment acted in a
promoter-specific manner. To answer this question, this fragment
was cloned upstream of the thymidine kinase promoter and en-
hancer (TKE), an ubiquitously active transcription driver widely
used for testing the effect of other cis-elements. We found that
the L fragment lost its response to Wnt3a when it was connected
to the TKE (Figure 5D), suggesting that communication with
cis-elements in the P6P plays critical roles in its response to
Wnt3a.
The pathways involved in activating the L fragment were
also examined and we found that LiCl only marginally instig-
ated the activity of MyoD-P6P-L-luc (Figure 5E). Although
the composite reporter MyoD-PE-L-luc could be activated by
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Figure 3 Wnt3a activates MyoD expression through multiple pathways
(A) MyoD-PE-Luc was transiently co-transfected with vectors expressing dominant-negative (DN) mutants of Wnt pathway
downstream effectors into C2C12 cells treated with or without Wnt3a. Luciferase activity was determined 24 h after
transfection and their relative activation by Wnt3a is shown. (B) C2C12-MyoD-PE-luc stable clones were treated with
Wnt3a in the presence or absence of MAPK inhibitors or A23187 for 48 h, and their relative activation by Wnt3a is
shown. (C) Increasing amount of engrail–β -catenin (EN-β -catenin) was co-transfected with MyoD-PE-Luc into C2C12 cells
as described in (A). (D and E) C2C12-MyoD-PE-luc stable clones were treated with Wnt3a or LiCl or neither (D) or increasing
amounts of LiCl alone (E) for 48 h, and their activity relative to Py or vehicle control is shown. *P < 0.05 and **P < 0.01
compared with vector or vehicle control.
LiCl dose-dependently, however, this activation was not much
different from that activated by Wnt3a (Supplementary Fig-
ures S1A and S1B). Bioinformatics analysis of its sequence
did not find conserved (matrix similarity >0.9) TCF/LEF- or
NFAT-binding sites; however, a Pax3/Pax7 target site (Pax3 and
Pax7 bind identical DNA motifs [33]) were found in this re-
gion. Treatment with JNK inhibitor or Ca2 + ionophore had no
effect on Wnt3a-activated L fragment activity (Figure 5F), sug-
gesting that neither pathway was involved. In contrast, deletion
of the putative Pax3/Pax7-targeted site ( − 9353 to − 9334, 5′-
GATGTCATGGGTACATAAT-3′) significantly reduced its activ-
ation by Wnt3a (Figures 6A and 6B), suggesting that activated
Pax3/Pax7 partially mediates Wnt3a effects on the L fragment.
Using qRT-PCR, the expression of both Pax3 and Pax7 in
C2C12 myoblasts was demonstrated (Figure 6C). The levels of
Pax7 protein were also examined (Supplementary Figure S2),
and we found further that Pax7 bound to this putative target site
in vivo, albeit with much weaker affinity than that in the previ-
ously identified Id3 gene [34], implying that this site is a bona
fide, but weak, Pax3/Pax7 target site mediating the Wnt3a effect
(Figure 6D). As the involvement of Pax3/Pax7 in the transduction
of Wnt3a signalling has not been reported previously, the details
of this novel mechanism by which Wnt3a triggers Pax3/Pax7 to
activate the L fragment remains to be determined, clarification of
which might shed new light on Wnt signalling transduction and
activation of downstream effectors.
DISCUSSION
Wnt3a functions as an upstream regulator of
myogenesis
Wnt3a has been shown to enhance the generation of multipo-
tential mesendodermal (including myogenic) progenitors from
embryonic stem cells and the myogenic differentiation of P19
embryonic carcinoma cells [35,36]. It is expressed not only in
the neural tube, but also in the epiblast transgressing primitive
streak that become the precursors of mesodermal and endodermal
progenitors [37]. Wnt3a-null mice show normal anterior (1–7)
somites, but defective posterior (after somite 7) somites, sug-
gesting its essential role in the somitogenesis of trunk paraxial
mesoderm, in which Wnt3a seems to function as a bridge link-
ing the node/organizer derived wave front (mainly Fgf8) and the
Notch pathways to regulate the periodic/cyclic epithelization of
presomitic mesoderm [38]. However, whether the Wnt3a signal
directly activates the expression of myogenic determination reg-
ulators, either Myf5 or MyoD, in somites has not been examined.
Therefore the direct regulation of MyoD activation by Wnt3a ob-
served in the present study is the first reporting this observation.
In adult SKM, quiescent satellite cells express undetectable
or very low levels of Myf5 or MyoD, and they start to actively
express MyoD upon the induction of proliferation signals, such as
exercise and muscle damage. The effect of MyoD on satellite cell
replenishment and their ability to regenerate damaged tissue is
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Figure 4 Constitutively active β-catenin enhances MyoD expression
(A) Transient transfection of MyoD-PE-luc and β -catenin expression vectors into C2C12 cells and the luciferase activity
was assayed 48 h after transfection. 90 and 151 represent N-terminally truncated β -catenin without the first 90 and
151 amino acids respectively. (B) C2C12 stable clones carrying either Py or Py-β -catenin 151–FLAG were established
and their β -catenin 151–FLAG levels were examined by Western blotting with anti-FLAG antibody. Gapdh served as a
control. (C) Myotube morphology and fusion index (%) after 4 days in differentiation medium. (D) Relative MyoD mRNA
levels in these stable clones of various stages [proliferating myoblast (PMB), confluent myoblast (CMB) and myotube (MT)]
were determined by qRT-PCR. (E) Binding of β -catenin 151–FLAG to the TCF/LEF sites in the MyoD gene DE region was
examined by ChIP assay. Chromatin of the C2C12-β -catenin 151–FLAG cells at the CMB stage was precipitated with
anti-FLAG antibody or control IgG and then the DNA was amplified with the indicated primer sets (P1–P3). The signals of
Dickkopf-related protein 1 (DKK1) and M-cadherin serve as positive and negative controls respectively. The amplicon of
each primer set is shown to the right. *P < 0.05 and **P < 0.01 compared with vector or vehicle control.
dose-dependent, whereby high MyoD levels repress satellite cell
self-renewal and drive their myogenic differentiation or apoptosis
[10]. Although previous studies have shown both positive and
negative effects of Wnt3a on adult muscle regeneration [21], the
observed adverse effect of Wnt3a on adult muscle regeneration
is probably an artefact caused by the constitutive overdose of
MyoD that was induced by Wnt3a.
The beneficial effects of Wnt3a are supported by the observa-
tion that exercise induces several Wnts in SKM, which in turn
promote myogenesis by activating the proliferation and differ-
entiation of residential satellite cells [39]. The same study also
demonstrated the increased binding of β-catenin/LEF to a TCF-
binding site located in the 2.7k and 2.4k regions of the MyoD and
Myf5 promoters respectively after voluntary exercise. Although
the binding of β-catenin/LEF to this TCF-binding site was not
examined in this study, this site might mediate the week activa-
tion of the MyoD-P6P-luc reporter by Wnt3a (Figure 2B). The
detailed promoter analysis performed in the present study has
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Figure 5 Cis-elements between the DE and the P6P also mediate the Wnt3a response
(A) Genomic fragments between the DE and the P6P were inserted into the MluI site in MyoD-PE-luc and their response
to Wnt3a is shown in (B). SP, a random vector sequence (1 kb) without known transcription factor-binding sites serves
as a non-specific spacer. All reporters used were stably carried by C2C12 cells. (C) C2C12 stable clones carrying either
MyoD-PE-luc or MyoD-6.0-L-luc were treated with Wnt3a and their luciferase activity was determined 48 h after treatment.
*P < 0.05 and **P < 0.01 compared with vehicle (Py) control. (D) Transient transfection of reporters into C2C12 cells to
test their response to Wnt3a as described in Figure 1(C). TOP/FOP, TOPflash/FOPflash; TKE: thymidine kinase promoter
and enhancer driven reporter; TKE-L: reporter driven by L fragment plus TKE. (E and F) C2C12 stable clones carrying
various MyoD cis-elements were treated with Wnt3a and/or its downstream pathways inhibitors or agonists to identify
pathways mediating the activation of the L fragment.
identified two other key Wnt3a-targeted sites in the MyoD up-
stream region (Figures 4 and 6) and it will be interesting to know
whether exercise-induced Wnts, including Wnt3a, can also target
these sites to activate MyoD expression in satellite cells.
The cis-elements regulating MyoD expression
Previous studies on the regulation of MyoD expression mainly
focus on the DE and the two regulatory regions (PRR and DRR)
in the P6P [13,14]. The positive-feedback regulation of MyoD is
mediated by E-box P1 and P2 located in the proximal promoter
[40], and an activator protein 1 (AP1) site ( − 342 to − 32) in the
same region represses MyoD activation [41]. A highly conserved
core sequence of 258 bp in the distal enhancer is capable of driv-
ing LacZ expression in a spatiotemporal pattern indistinguishable
from endogenous MyoD during embryogenesis; however, it is
dispensable for Myf5- and Pax3-dependent regulation of MyoD
transcription, and its deletion does not cause obvious defects in
myogenesis [42,43]. The DRR enhancer is essential for MyoD
expression in postnatal muscle and it contains a CArG element
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Figure 6 The L fragment mediates the Wnt3a response via canonical and Pax3/Pax7-mediated pathways
(A) Schematic diagrams of the locations of the Pax3/Pax7-binding site in the L fragment. (B) C2C12 stable clones carrying
P6P-L or P6P-L-Pax3/7 were treated with vehicle or Wnt3a. **P < 0.01 compared with Py; ##P < 0.01 compared with
Wnt3a-treated P6P-L-luc. (C) The relative mRNA levels of MyoD, M-cadherin (M-cad), Pax3 and Pax7 in CMB C2C12 cells
treated with or without Wnt3a were examined with qRT-PCR. The mRNA level of each gene in cells treated with Py medium
was set as 1-fold. **P < 0.01 compared with Py. (D) ChIP assay of vehicle or Wnt3a-treated C2C12 cells with IgG or
anti-Pax7 antibody and the primer set (L1) shown in (A). The signals of the Id3 gene serve as a positive control of the
Pax7-targeted site. NTC, no template control.
targeted by both serum-response factor (SRF) and myocyte en-
hancer factor 2 (MEF2) protein for initiation and maintenance of
MyoD expression in satellite cells [44]. Both the core enhancer
and DRR are targeted by Six1/Six4 homeoproteins for particip-
ating in the Pax3/MyoD genetic pathway [45]. Expression of
MyoD in SKM can also be activated by thyroid hormone (3,3′,5-
tri-iodothyronine or T3) and the T3-response element (TRE) has
been located to the − 337 to − 309 region of the proximal pro-
moter [46]. However, the analysis of other cis-elements regulating
MyoD expression has been hindered by the strict requirement of
both DRR and PRR in a region that extends over a sequence of
6.0 kb, i.e. the P6P, and the fact that promoters shorter than this
or that lack either region show very low or undetectable activity
(results not shown).
Owing to the requirement of the P6P, very few previous studies
have been devoted to analysing the contribution of cis-elements
outside the DE and the P6P in the MyoD gene, and, to our know-
ledge, the present study is the first one analysing the contribution
of the intervening region between the DE and the P6P to MyoD
expression. The identification of the strong response of the L
fragment to Wnt3a shows the important involvement of the inter-
vening regions in the regulation of MyoD expression. Besides,
several fragments (E, F, N and K) in this region have repressed
the Wnt3a-activated MyoD-PE-luc activity, implying that they
contain critical negative regulatory cis-elements that prevent the
haphazard expression of MyoD in cells of other lineages. More
endeavours in the future should be devoted to analysing their tar-
geting factors and interactions/cross-talk with other cis-elements
in the DE and the P6P to reveal the mechanism of the tightly
restricted expression of MyoD in SKM.
Moreover, although MyoD has been known for more than two
decades, its induction, but not forced expression, in cells of other
lineages has not been successful to turn these cells into muscle-
forming myoblasts [47]. With the carefully constructed MyoD
gene reporters set up in the present study, it will allow us to
identify the direct targeting sites of various activating signals,
such as retinoic acid, and repressing signals, such as Shh, in the
MyoD gene more easily, which in turn should reveal the mechan-
isms governing the SKM-specific MyoD expression. The unrav-
elled mechanisms might pave the way for reprograming cells of
non-muscle lineages into MyoD-expressing myoblasts for treat-
ing degenerating muscle diseases, such as Duchenne muscular
dystrophy.
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